Leerink Partners Maintains Outperform on Edwards Lifesciences, Raises Price Target to $112
Benzinga Newsdesk 6 hours ago
Analyst RatingsNewsPrice TargetHot
Leerink Partners analyst Mike Kratky maintains Edwards Lifesciences (NYSE:EW) with a Outperform and raises the price target from $101 to $112.
Leerink Partners analyst Mike Kratky maintains Edwards Lifesciences (NYSE:EW) with a Outperform and raises the price target from $101 to $112.